• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol Methods. Evaluation of Nanogen MGB Alert((R)) Detection Reagents in a multiplex real-time PCR for influenza virus types A and B and respirator

Giuseppe

Emeritus
J Virol Methods. 2008 Dec 2. [Epub ahead of print]

Evaluation of Nanogen MGB Alert((R)) Detection Reagents in a multiplex real-time PCR for influenza virus types A and B and respiratory syncytial virus.

Hymas WC, Hillyard DR. - Associated Regional and University Pathologists (ARUP), Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, United States.

A multiplex real-time RT-PCR assay that detects influenza A, influenza B and respiratory syncytial virus (RSV) using the MGB Alert((R)) Influenza A&B/RSV Detection Reagent RUO (Nanogen, San Diego, CA) was developed.

The Nanogen detection reagents consist of PCR primers and minor groove binder-conjugated hybridization probes for each virus and an internal control.

Virus typing was determined by post-PCR melt curve analysis.

A non-competitive armored RNA internal control was co-extracted with each sample to monitor nucleic acid extraction and RT-PCR.

The assay was evaluated using a collection of culture, DFA and RT-PCR (Hexaplex, Prodesse, Waukesha, WI) positive and negative samples.

The real-time multiplex assay detected 236 of 237 positive specimens for a 99% correlation.

Of 30 Hexaplex negative samples tested, the multiplex real-time assay detected an additional 7 positives confirmed using additional PCR assays.

Melt curve analysis for each virus produced average melting peaks of 60.4 degrees C, 66.7 degrees C and 69.4 degrees C for influenza A, influenza B and RSV respectively.

Sequence analysis of 7 influenza A samples producing aberrant melt curves, confirmed the presence of a single nucleotide polymorphism beneath the influenza A probe.

The limit of detection of each virus in 4 different sample types was measured to be between 7 and 806 copies.

Overall, the multiplexed real-time RT-PCR assay was sensitive, robust and easy to use.

PMID: 19061916 [PubMed - as supplied by publisher]
-
------
 
Back
Top